Navigation Links
Mediaplanet Releases a Campaign to Reflect on 100 Years of Alzheimer’s Research and the Quest for a Cure
Date:6/13/2013

New York, NY (PRWEB) June 13, 2013

A recently launched digital platform unveils a new breakthrough in Alzheimer’s research that is putting us on the brink of discovering a cure. This digital campaign, created by Mediaplanet, also explains the important role that clinical trials has and will continue to play in the quest for a cure.

Click to access the full site: Understanding Alzheimer's

Alzheimer's strikes one in eight Americans, and is the sixth leading cause of death in the United States. The disease not only affects the person who has it – it also has a profound emotional and financial impact on their families and loved ones. For society as a whole, Alzheimer’s poses a significant financial burden and greatly contributes to the rising cost of healthcare. More concerning is the fact that current treatments do not halt the disease’s progression—they only address the symptoms.

Researchers from around the world are tirelessly searching for a more effective treatment that can actually stop, or even reverse, Alzheimer’s progression. One of them is Professor Claude Wishik, M.D., Ph.D. and chairman of TauRx Therapeutics. He has been searching for an Alzheimer’s cure for nearly 30 years.

In Alzheimer’s patients, the brain actually shrinks as nerve cells die and tissue disappears. The dead and dying cells contain twisted strands of protein called "tangles.” Professor Wischik is convinced that these tangles and the protein they are made of, tau, play a central role in the disease. He recently entered Phase 3 clinical trials for a drug focused primarily on stopping the tau tangles from developing. The clinical trials, which started late last year, are testing a drug called LMTX™, which he believes could be the first treatment to halt the progression of Alzheimer’s disease.

Clinical trials are of utmost importance when it comes to testing the safety and efficacy of any new drug. “You can argue theories until you are blue in the face, but the proof is finding a drug that works, and the only way that can be obtained is through clinical trials. You can do other studies, but nobody will believe it until it’s proven in man,” Professor Wishik says.

Clinical trials are not only crucial to drug development; they can also benefit the participants. “Patients get cutting edge therapies, and the clinical trials don’t preclude them from the currently available therapies. It gives them hope that something may work,” he notes. He urges those affected by the disease– patients and caregivers, – to seek help as quickly as possible: “Run, don’t walk! Seek help, make a noise, talk about it and seek support!”

Mediaplanet publishes focused print and digital campaigns on specific business, healthcare, technology or consumer topics.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10829836.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Mediaplanet Releases Autoimmune Awareness Campaign Within The Washington Post
2. Oro Gold Cosmetics Releases New Product Based On The Latest Research To Fight Cancer And Reverse Aging
3. Narconon Arrowhead Releases Outcome Monitoring Reports
4. Dr. Bonnie Weil Releases Course on Successful Relationships
5. OutcomesMTM Releases Inaugural “Trends Report”
6. Clean Water Systems & Stores Inc Releases the New Updated Complete Guide to Removing Odors from Well Water
7. Iowa Chronic Care Consortium Releases Study Results of Health Coaching Survey
8. Upstart Bachelorista Inc. Releases Tell-All Playbook For Single Women
9. Discount One Direction Tickets: QueenBeeTickets.com Releases New Inventory of One Direction Tour Tickets as the Band Gets Ready to Return to the United States
10. Orriant Releases Corporate Wellness Case Study Results Highlighting the Success of a Police Sergeant and His Family
11. Palomar Modular Buildings Releases Education Project Case Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology: